Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia.
Ontology highlight
ABSTRACT: Multidrug resistance, a major problem that leads to failure of anticancer chemotherapy, requires the development of new drugs. Repurposing of established drugs is a promising approach for overcoming this problem. An example of such drugs is niclosamide, a known anthelmintic that is now known to be cytotoxic and cytostatic against cancer cells. In this study, niclosamide showed varying activity against different cancer cell lines. It revealed better activity against hematological cancer cell lines CCRF-CEM, CEM/ADR5000, and RPMI-8226 compared to the solid tumor cell lines MDA-MB-231, A549, and HT-29. The multidrug resistant CEM/ADR5000 cells were similar sensitive as their sensitive counterpart CCRF-CEM (resistance ration: 1.24). Furthermore, niclosamide caused elevations in reactive oxygen
SUBMITTER: Hamdoun S
PROVIDER: S-EPMC5344920 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
ACCESS DATA